AMERICAN CANCER SOCIETY and FLATIRON HEALTH, INC

REAL WORLD DATA IMPACT AWARD POLICIES

EFFECTIVE JANUARY 2024

ELECTRONIC APPLICATION DEADLINE: April 1, 2024

AMERICAN CANCER SOCIETY, INC.
Extramural Discovery Science Department

Web site: http://www.cancer.org
Program Contact: kimberly.clarke@cancer.org

MISSION
The American Cancer Society’s mission is to improve the lives of people with cancer and their families through advocacy, research, and patient support, to ensure everyone has an opportunity to prevent, detect, treat, and survive cancer.
# Table of Contents

1. DESCRIPTION OF THE REAL-WORLD DATA IMPACT AWARD ........................................ 3
2. ACS EXTRAMURAL DISCOVERY SCIENCE RESEARCH PRIORITIES .......................... 3
3. APPLICANT ELIGIBILITY ............................................................................................. 5
4. ELIGIBLE INSTITUTIONS AND INSTITUTIONAL RESPONSIBILITIES ...................... 6
5. GRANT BUDGET AND TERM ..................................................................................... 7
6. APPLICATION DEADLINE .......................................................................................... 8
7. NOTIFICATION OF APPLICATION RECEIPT AND REVIEW ..................................... 8
8. PEER REVIEW OF APPLICATIONS ........................................................................... 8
9. GRANT ACTIVATION AND PAYMENTS ...................................................................... 9
10. GRANT PROGRESS REPORTS .................................................................................. 9
11. FINANCIAL RECORDS AND REPORTS ................................................................... 9
12. INTELLECTUAL PROPERTY RIGHTS ..................................................................... 10
13. PUBLICATIONS AND OTHER GRANT-RELATED COMMUNICATIONS .................. 12
14. GRANT MODIFICATIONS ......................................................................................... 12
15. CANCELLATION OF GRANT .................................................................................. 13
16. ADDITIONAL ACS GRANT POLICIES ................................................................... 13

APPENDIX A: GUIDELINES FOR MAINTAINING RESEARCH AND PEER REVIEW INTEGRITY .................................................................................................................... 14
1. **DESCRIPTION OF THE REAL-WORLD DATA IMPACT AWARD**

The Real-World Data Impact Award (RWIA) supports the American Cancer Society’s and Flatiron Health, Inc. (FHI)’s goals of accelerating cancer research that informs public health, public policy, and ultimately improves clinical practice.

This Request for Applications (RFA) is a call for investigators to propose cancer research questions which utilize Flatiron Health’s electronic health record (EHR)-derived database from approximately 280 US cancer clinics (~ 800 sites of care). Flatiron Health, Inc. (FHI) extracts and processes both structured and unstructured data from hundreds of thousands of patients’ electronic health records. With this real-world data, FHI has developed 22 disease-specific longitudinal datasets with 30-day recency. The goal of this RFA is to capitalize on the FHI datasets, where the health records of patients with cancer can inform how we treat and care for all patients with cancer. Interested applicants are encouraged to review published research that utilized FHI data.

2. **ACS EXTRAMURAL DISCOVERY SCIENCE RESEARCH PRIORITIES**

The American Cancer Society has established six areas to prioritize the research we fund to help advance our mission. Applicants are expected to explain how their proposed research integrates into at least one of the research priorities and advances the mission of the ACS.

- **Etiology**
  The American Cancer Society supports research into the causes of cancer and the incidence, initiation, and biology of cancers. To accelerate progress in understanding the causes of cancer, this priority area supports research to identify early, inherited, somatic, molecular, behavioral, environmental, and societal causes and risk factors impacting cancer incidence, progression and mortality. Research in this priority area could include:
  - Understanding fundamental cellular processes in carcinogenesis including DNA damage, hypoxia, and extracellular matrix remodeling.
  - Developing new cancer models to understand the intersection of genetics and exposures for cancer initiation.
  - Understanding factors that contribute to tumor evolution including the adaptive immune system and its interplay with innate responses.
  - Identifying and characterizing target genes involved in cancer using global scale genomic and epigenomic approaches.

- **Obesity/Healthy Eating and Active Living (HEAL)**
  The American Cancer society supports research on diet, metabolism, physical activity, and nutrition-related factors to better understand these factors roles in cancer risk, progression, treatment, and survivorship. Studies can span the research continuum (i.e., from molecular to population). Research in this priority area could include:
  - Determining how nutritional and environmental factors (including tumor microenvironment) alter cellular metabolism and impact cancer development, disease progression, recurrence, and survivorship.
  - Studying how body size and body composition (adiposity, lean mass) impact cancer treatment, prognosis, and survivorship.
  - Testing evidence-based interventions that lead to the adaptation of a healthy diet and/or adequate levels of exercise/physical activity.
• Screening and Diagnosis
The American Cancer Society supports research on cancer screening and early detection, diagnostics, and prognostics. We encourage studies focused on high mortality cancers and major cancer types lacking screening tests. Studies can span the research continuum (i.e., from molecular to population-based). Research in this priority area could include:
  o Discovery and development of new screening opportunities, surveillance, and risk assessment, including developing or advancing technologies that could lead to reducing the burdens of cancer.
  o Development of diagnostic tests to distinguish high-risk early lesions from those that do not necessitate rushing into curative therapy incurring unnecessary side-effects and financial toxicity.
  o Improving understanding of the cellular and molecular underpinnings of the earliest stages of cancer and premalignant disease, with a focus on subtypes associated with health disparities.
  o Understanding and identifying barriers and social determinants of health that interfere with the adoption of recommended guidelines and/or the testing of innovative strategies to increase and sustain their uptake, equity, and effectiveness.

• Treatment
The American Cancer Society supports research to develop new cancer treatments, targets, and systems to monitor and treat resistant disease and to enhance opportunities in immunotherapy and precision medicine. To accelerate progress in cancer treatment, this priority area supports research to improve models and test interventions for prevention, tumor dormancy, recurrence, resistance, and metastasis. This priority area will further generate predictive preclinical models to streamline clinical testing of combination or multi-modal therapies by funding research on tumor microenvironment, heterogeneity, microbiome, and immune escape. Research in this priority could aim to improve timely access to treatment, increase participation rates of diverse populations in clinical trials and advance our understanding of barriers to receipt of timely and high-quality treatment. Research in this priority area could include:
  o Identifying new agents, combinations, and approaches useful in cancer therapy.
  o Developing and integrating interventions which reduce barriers and social determinants of health that interfere with cancer treatments.
  o Development of systems to predict, and monitor for, resistance to treatment.

• Survivorship
Survivorship research focuses on improving the survivorship journey for cancer survivors and their caregivers including physical, emotional, financial, spiritual, and supportive services or care delivery and communication research. Research may address access barriers to high quality cancer care and health equity across the cancer continuum - screening and early detection, diagnosis, treatment, or palliative care and survivorship and may include:
  o Improving the quality of care and quality of life for survivors and caregivers will include assessment of survivor and caregiver needs, assessment of survivor
function, improving communication and decision making with health care professionals and caregivers, effective care coordination, and integrating early primary and specialty palliative care into interventions that personalize and tailor care.

- New models of delivering care and interventions inclusive of interdisciplinary approaches and economic evaluation: i.e., novel strategies for coordinating care between specialists and primary care providers; telehealth/virtual care; virtual reality; or artificial intelligence.

- Improving risk prediction models, tools, and standardization of real-world data to inform improvements in practice, public health, and public policy.

- Molecular and cellular mechanisms underlying symptoms, adverse events, and co-morbidities that persist throughout survivorship.

**Health Equity across the Cancer Control Continuum**

The American Cancer Society believes that everyone should have a fair and just opportunity to prevent, find, treat, and survive cancer. Societal issues such as poverty, education, social injustices, unequal distribution of resources and power underpin profound inequities. These macro-environmental conditions where people are born, grow, live, work and age along with the available systems supporting health are known as the social determinants of health (SDOH). The SDOH are interrelated and extend across the life span to impact health. This area of research addresses the interplay between SDOH and access to high quality care and services across the cancer continuum and solutions to achieve optimal outcomes for all. Research may include:

- Multilevel research and multilevel interventions addressing root causes of cancer health disparities related to SDOH including classism and structural racism leading to improved health outcomes.

- Implementation research involving underserved communities to test novel strategies for getting research evidence into clinical and public health practice; culturally tailored approaches to increase participation and overcome barriers for adherence to study protocols.

- Testing interventions addressing financial barriers, cost benefit, cost effectiveness and implications of health insurance and health policy on care across the cancer continuum.

- Increasing participation of diverse subjects in clinical trials to increase participation, overcome barriers and improve generalizability.

### 3. APPLICANT ELIGIBILITY

- Applicants must be an independent researcher at an eligible US academic institution or non-profit.

- Applicants must have the necessary training and expertise to conduct research projects using de-identified real-world data.

- All applicants shall be subject to the terms and conditions of a separate confidentiality agreement between Flatiron Health, Inc and the Grantee. All awardees will be required to comply with the FHI data use agreement which outlines the terms and conditions required for the Grantee’s use, receipt and storage of FHI licensed data.

- Current and former RWIA grantees are not eligible to apply but may be a Co-Investigator or Collaborator on an application.
• Applicants may only submit one project to the RFA.
• The Society allows only one individual to be designated as principal investigator, responsible and accountable for the overall conduct of the project.

4. ELIGIBLE INSTITUTIONS AND INSTITUTIONAL RESPONSIBILITIES
The Society’s grants and awards are made to not-for-profit institutions physically located within the US and its territories. Eligible institutions should be able to provide:

• A current letter from the Internal Revenue Service conferring nonprofit status;
• Evidence of an active research program with a track record of extramural funding and publications in peer reviewed journals; and
• Documentation of appropriate resources and infrastructure to support the proposed research. These include, but are not limited to:
  o Adequate facilities and services;
  o Fiscal and grants management infrastructure to ensure compliance with ACS policies, and with federal policies regarding protections for human and animal subjects (e.g., a sponsored-projects office or a contract with an IRB or IACUC);
  o A process for appointment and promotion equivalent to those in academic settings for staff scientists for grant mechanisms limited to early career researchers; and
  o Evidence of education, training, and mentoring for fellows and beginning researchers if appropriate for the grant mechanism.

Grant applications will not be accepted, nor will grants be made, for research conducted at

• For-profit institutions;
• Federal government agencies (including the National Laboratories);
• Organizations supported entirely by the federal government (except postdoctoral fellowship applications);
• Organizations that primarily benefit federal government entities, such as foundations operated by or for the benefit of Veterans Affairs Medical Centers (VAMC). However, qualified academic institutions may submit applications on behalf of a VAMC if a Dean’s Committee Memorandum of Affiliation is in effect between the 2 institutions.

The American Cancer Society does not assume responsibility for the conduct of the activities that the grant supports, or for the acts of the grant recipient, because both are under the direction and control of the grantee institution and subject to its medical and scientific policies. The institution of the PI is responsible for the accuracy, validity, and conformity with the most current institutional guidelines for all administrative, fiscal, and scientific information in the application.

Every grantee institution must safeguard the rights and welfare of individuals who participate as subjects in research activities by reviewing proposed activities through an institutional review board (IRB), as specified by the National Institutes of Health Office for Human Research Protections of the US Department of Health and Human Services (DHHS).

Furthermore, applicants, applicant institutions, and grantee institutions must adhere to DHHS guidelines as well as ACS guidelines regarding conflicts of interest, recombinant DNA, scientific misconduct, and all other applicable ACS policies and procedures.

To signify agreement with all ACS policies and procedures, an application for a grant must bear the e-signature of the principal investigator. Space is provided for e-signatures for the
departmental chair (or equivalent) and institutional official to accommodate institution-specific requirements for proposal submissions, but neither are required for submission to ACS.

Once a grant is awarded, an institutional official signature’s is required signifying institutional agreement with all ACS policies and procedures. The institution is responsible for verifying that all documentation related to the grant is correct, including all representations made by any named researcher (e.g., position or title). Further, the institution is responsible for verifying that the grantee is either a US citizen, a permanent resident with a Resident Alien Card (“Green Card”) where applicable, or a non-citizen with required US government visa status. If the award does not require US citizenship or permanent residency, the institution is responsible for documenting the grantee’s legal eligibility to work in the US for the duration of the award.

The institution is required to ensure IRB approval is obtained for the grant to start, and the approval documentation is uploaded into ProposalCentral within 3 months of grant activation. Furthermore, IACUC approval must be obtained before animal work begins. An IACUC approval letter must be uploaded to ProposalCentral immediately upon approval.

It is the responsibility of the institution to immediately report to ACS any finding that any information presented to ACS in connection with the application and/or grant is false. It is also the responsibility of the institution to immediately report to ACS any action including recertification, loss of certification, breach of contract, misconduct, or change in employment status for a named researcher with the institution. This includes administrative leave, which may occur during the term of any award, pertinent to the work described in the grant application.

Failure to abide by the terms above, or by any other ACS policy or procedure, may result in suspension or cancellation of the grant, at the sole discretion of ACS.

By accepting an American Cancer Society award, you agree to the Guidelines for Maintaining Research and Peer Review Integrity found in the Appendix of these policies.

5. GRANT BUDGET AND TERM
The award is for a 1-year term with up to $75,000 total costs; indirect costs are not allowed. Personnel may receive salary support up to the National Institutes of Health salary cap, prorated according to their percent effort on the project. Budgets submitted must be realistic estimates of the funds required for the proposed research.

A. EXPENDITURES
American Cancer Society research grants are not designed to cover the total cost of the research proposed or the investigator’s entire compensation. The grantee’s institution is expected to provide the required physical facilities and administrative services normally available at an institution.

It is the recommendation of the Society not to exceed the accumulated monthly installments of the grant. In the event of a cancellation or transfer, the institution is only entitled to the prorated amount of the award accumulated between the start and end dates (See Section 19, Cancellation and Transfer of Grant).

The Society is flexible in response to the changing needs of a research program. The Principal Investigator may make minor alterations (changes <$15,000/year) within the approved budget except where such expenditures conflict with the policies of the Society.

Major changes in expenditures (>$15,000 per year) require written approval from your Scientific Director. For permanent equipment, the annual threshold requiring written approval is >$5,000. The PI should contact the Scientific Director for guidance.

The Society’s research grants do NOT provide funds (direct costs) for such items as:
- **Administrative**
  - Administrative salaries
  - Membership dues
- **Tuition, books, and fees**
  - Student tuition and fees (graduate or undergraduate).
  - Books and periodicals
- **Office or laboratory setup and expenses**
  - Office and laboratory furniture
  - Office equipment and supplies
  - Rental of office or laboratory space
  - Construction, renovation, or maintenance of buildings or laboratories
- **Other**
  - Recruiting and relocation expenses
  - Non-medical services to patients (travel to a clinical site or patient incentives are allowable expenses)

Society research grant funds may be used for computers for research purposes, which can be purchased with direct funds from the equipment budget. In addition, the Society’s research grants may provide funds (direct budget) for foreign travel, but this requires **pre-approval** by your Scientific Office.

**B. OWNERSHIP OF EQUIPMENT**

Equipment purchased under ACS research grants or grant extensions is for use by the principal investigator and collaborators. Title of such equipment shall be vested in the institution at which the principal investigator is conducting the research. In the event the ACS authorizes the transfer of a grant to another institution, equipment necessary for continuation of the research project purchased with the grant funds may be transferred to the new institution, and title to such equipment shall be vested in the new institution.

**6. APPLICATION DEADLINE**

Applications for awards under the ACS-FHI Real World Data Impact Award RFA must be submitted electronically via proposalCentral by **11:59 PM ET on April 1, 2024**. Applications will only be accepted from investigators who submitted a letter of intent (LOI) and were invited to apply. No supplemental materials will be accepted after the deadline unless requested by ACS staff or reviewers.

**7. NOTIFICATION OF APPLICATION RECEIPT AND REVIEW**

Less than one month after receipt of the application, applicants will receive an email acknowledgement providing an application number and the name of their Scientific Director with contact information. This email will be sent to the address in the professional profile supplied at the time of submission in proposalCentral. Be certain the email address listed in your professional profile is active, since it will be used to notify you throughout the review and award process.

Following the two-tier review process, applicants will be notified of the outcome of review and will be given access to reviewer critiques and Flatiron Health, Inc’s assessment.

**8. PEER REVIEW OF APPLICATIONS**

Scientific review of applications will be conducted by a special peer review panel established to review the RWIA applications. Each application will be assigned to at least 2 scientific reviewers and one stakeholder (usually no formal training as a scientist or health professional but has a strong personal interest in advancing the effort to control and prevent cancer through research) for independent and confidential review.
Peer review committees use application evaluation criteria that vary depending on the grant mechanism. See application instructions for details.

The peer review committee discusses, scores, and ranks the applications. The ranking, critiques, and discussion are then used to make funding decisions by our Council.

9. GRANT ACTIVATION AND PAYMENTS

New grantees will receive a packet of information with instructions for activating the award. The activation form as well as other important information about the grant can also be found at https://proposalcentral.com/ (select the Award tab to see the Post Award Management site).

Grant payments will be made at the end of each month. The ACS makes all payments to the sponsoring institution via electronic funds transfer or via a mailed check depending on the preference selected on the grant activation form.

Acknowledgement of payment by the sponsoring institution is not required. Continued funding by ACS throughout the grant period is contingent upon the institution’s compliance with all terms related to the grant; failure to comply with all the grant terms may result in a suspension or cancellation of the grant, to be determined by ACS at its sole discretion.

Personnel compensated in whole or in part with funds from the ACS are not employees of the Society. Consequently, institutions are responsible for issuing appropriate IRS tax filings for all individuals receiving compensation from ACS grants, and for withholding and paying all required federal, state, and local payroll taxes for such compensation. Any tax consequences are the responsibility of the individual recipient and the sponsoring institution. We advise all grant and award recipients to consult a tax advisor regarding the status of their awards.

10. GRANT PROGRESS REPORTS

Timely scientific and financial reports represent a critical part of responsible stewardship of the donated dollars. We greatly appreciate your efforts to assist us in fulfilling these important commitments. Information in the annual and final scientific reports, as well as possibly from the General Audience Summary, may be shared with donors under a Non-Disclosure Agreement. Therefore, do not include proprietary or confidential information. To access the forms for annual and final progress reports, go to https://proposalcentral.com/ under the “Deliverables” tab in post-award management.

An annual progress report must be submitted each year within 60 days after the first and subsequent anniversaries of the start date of the grant. Additionally, the PI institution’s Technology Transfer Officer (TTO) is required to submit an annual intellectual property report.

Final progress reports are due within 60 days after the grant has terminated. The final report should cover the entire grant period. In the event a grant has been extended without additional funds, the final report is not due until 60 days after the official termination date of the grant. If the grant is terminated early, a final report must still be completed within 60 days of the termination date.

Grantees must submit reports in a timely manner. If this is not possible, a grantee must make a written request to extend the reporting deadline. Noncompliance may result in the withholding of payment on all grants in effect at the recipient institution until reports are received.

Please note that up-to-date annual reports are required when requesting any grant modifications, including transfer of institutions and no-cost extensions.

11. FINANCIAL RECORDS AND REPORTS

A report of expenditures must be submitted within 90 days of the grant’s termination date shown in the award letter; annual financial reports are not required. Any change in terms, such as a no-
cost extension, will alter a report’s due date. The necessary forms can be found under the “Deliverables” tab at https://proposalcentral.com/.

Signatures of the PI and the institution’s financial officer are required. Any unexpended funds must be returned to the Society.

Grantees must submit financial reports in a timely manner. If this is not possible, a grantee must make a written request to extend the reporting deadline. Noncompliance may result in the withholding of payment on all grants in effect at the recipient institution until reports are received.

Institutions must maintain separate accounts for each grant, with substantiating invoices available for audit by representatives of the ACS. The Society is not responsible for expenditures made prior to the start date of the grant, costs incurred after termination or cancellation of the grant, commitments against a grant not paid within 60 days following the expiration date, or any expenditures that exceed the total amount of the award. (See also Section 15 “Cancellation.”)

**12. INTELLECTUAL PROPERTY RIGHTS**

As a not-for-profit organization supported by public contributions, the Society wishes to adopt policies and practices that enhance the likelihood that potentially beneficial discoveries and inventions will be exploited to the benefit of humankind. It is the desire of the Society that such inventions be administered in such a manner that they are brought into public use at the earliest possible time. The Society recognizes that often this may be best accomplished through patenting and/or licensing of such inventions. Accordingly, the Society has adopted the following patent policy that is binding on all Grantees and Not-for-profit Grantee Institutions (hereinafter "Grantee"), excluding postdoctoral fellowship Grantees at the National Institutes of Health and other government laboratories, for whom the applicable patent policies of the federal government shall apply. To the extent the Grantee Institution’s own policies permit individual investigators to own any right, title or interest in any Funded Invention, the Grantee Institution shall ensure that each Investigator complies with the provisions of these terms and conditions with respect to such Funded Invention.

Acceptance of a Grant from the Society constitutes acceptance of the terms and conditions of this policy. In the event of any conflict between this policy and the Grantee’s policy, the terms and conditions of this policy shall govern.

**A.** All notices required pursuant to this policy shall be in writing, and in this policy, the following terms shall have the meaning set forth below.

i. "Invention" shall mean any potentially patentable discovery, material, method, process, product, program, software or use.

ii. "Funded Invention" shall mean any Invention made in the course of research funded in whole or in part by a Society Grant.

iii. "Gross Income" shall mean gross royalty income received by Grantee in respect of a Funded Invention inclusive of income from a single sale of the Funded Invention, less a total of $25,000 towards United States patent filing fees and an additional $25,000 USD for international patent filing fees.

iv. “ACS Award” shall mean the total monetary amount of the Grant provided to the Grantee.

**B.** The Grantee technology transfer officer shall provide the Society with an annual report for each Funded Invention. The annual report will be due by January 31 of each calendar year.
after an ACS Grant Award has been received. The annual report shall include a listing or description of the following information for each Funded Invention: (1) all issued patents and pending patent applications, (2) all licenses, leases, or other revenue generating agreements, (3) all gross revenue for each preceding calendar year, (4) the filing, publication and issuance or grant of any application for a patent or other statutory right for a Funded Invention, and (5) the latest stage of development of any product arising from each Funded Invention.

Grantee shall pay all costs and expenses incident to all applications for patents or other statutory rights and all patents and other statutory rights that issue thereon owned by Grantee (other than patent filing fees as provided for in Section A).

C. Both the Society and Grantee, (the appropriate Grantee technology transfer officer managing Funded Invention), shall promptly inform the other of any suspected infringement of any patent covering a Funded Invention and of any misappropriation, misuse, theft or breach of confidence relating to other proprietary rights in a Funded Invention. Grantee and Society will discuss in good faith further action to be taken in this regard.

D. Grantee will license a Funded Invention in accordance with Grantee Policy and established practices.

E. The Society waives the receipt of income until the Gross Income from the Funded Invention exceeds $500,000.

Once the Gross Income from a Funded Invention exceeds $500,000, Grantee shall pay the Society annually 5% of Gross Income. Such payment shall be accompanied by an appropriate statement of account. The income to the ACS from Grants other than Mission Boost Grants will not exceed four (4) times the amount of the total ACS Award. The income to the ACS from Mission Boost Grants will not exceed ten (10) times the amount of the total Mission Boost Award.

Payments shall be made on an annual basis by January 31, the year after the year that income was received. Should Grantee not be able to make a payment by January 31 for any calendar year in which income was received, Grantee shall inform the Society at least seven days prior to missing a payment. Grantee shall have a grace period of 90 days to make the missed payment. Failure to make payments after the 90-day grace period will be deemed a breach of this agreement. The Society shall have the right to audit, at the Society's expense, the Grantee's books and records annually.

The term of this Agreement shall extend until the expiration of the last to expire patent in any jurisdiction that covers the Funded Invention, or three years past decline of revenue to $0, or once the cap has been met.

F. Development and Commercialization of Funded Invention

The Society wishes to support and accelerate the commercialization and deployment of the results from Grantee's research. To help Grantee bring its Funded Invention to market as quickly as possible, Grantee shall inform The Society if Grantee decides to commercialize or seek investment in any Funded Invention. The Society requests that the Grantee offer The Society an opportunity to fund, facilitate, invest, or otherwise participate in such commercialization efforts via ACS BrightEdge, its impact venture capital fund (https://www.acsbrightedge.org/).

Please note that the American Cancer Society is unable to renegotiate the terms of this agreement with any individual institution.
13. PUBLICATIONS AND OTHER GRANT-RELATED COMMUNICATIONS

When and how to acknowledge your ACS grant:

Publications resulting from research supported by the American Cancer Society must contain the following acknowledgment: “Supported by [name of grant and number] from the American Cancer Society.” When there are multiple sources of support, the acknowledgment should read “Supported in part by [name of grant and number] from the American Cancer Society,” along with references to other funding sources.

The Society’s support should also be acknowledged by the grantee and the institution in all public communication of work resulting from this grant, including scientific abstracts (where permitted), posters at scientific meetings, press releases or other media communications, and internet-based communications. Grantees are encouraged to notify their scientific program office before public communication of their work so that external communication can be coordinated.

The American Cancer Society Extramural Discovery Science grant award process registers new grants with Crossref and assigns a Digital Object Identifier (DOI) number to each. The DOI number will allow tracking and identification of publications, patents, and other work that resulted from this grant award. The DOI link in ProposalCentral is located on the on the Award Details page. Your Crossref DOI link leads to a page of publicly available information about this grant award. The information on Crossref includes the grant number, the grant amount, the dates of the award, the title of the research project, the names of the investigators, the research institution, and the lay summary for the research.

Although there is no formal ACS approval process for publications by Society grantees, it is helpful to notify your Scientific Director when manuscripts have been accepted for publication. This will allow ample time for additional public or Society-wide notifications. If your institution plans a press release involving any of your Society-supported research, please notify your Scientific Director in advance.

ACS grants to you a limited, revocable, non-transferable license to use the ACS logo (as shown below) in association with your funded work. We encourage you to use it on scientific posters, Power Point presentations, and any other visual presentation about your funded work where the ACS is noted as a funding source. In turn, you agree to provide any materials featuring the ACS logo upon our request. Permission to use the logo is limited to the uses outlined in the above paragraph. It should not imply ACS endorsement of products such as guidelines, websites, software for mobile devices (apps), tool kits, and so on.

14. GRANT MODIFICATIONS

All Forms can be found under the Deliverables tab at https://proposalcentral.com/.

Please note that up-to-date annual reports are required prior to approval of any grant modifications including transfers and no-cost extensions.

- **No Cost Extension** (NCE) for up to 6-months may be requested by the PI. The NCE Request form should be uploaded to the Deliverables tab on ProposalCentral. The PI will be notified if the NCE is granted. Typically, the total dollar amount that is allowed to be carried over must be equal to or less than 6 months of direct costs.
• **Leave of absence**: Requests for a leave of absence will be handled on a case-by-case basis. If possible, please contact the Scientific Director at least 30 days prior to the proposed beginning of leave.

• **Request to transfer institution**: Grantees may transfer their grant from one institution to another eligible institution only after receiving written approval from the Society. Grant recipients must request a transfer as soon as a final decision for changing institutions has been made. Contact the Program Office to alert the Scientific Director of your intent to transfer.

The Society reserves the right to deny requests for extensions, leaves of absence, or transfers.

15. CANCELLATION OF GRANT
If a grant is to be canceled prior to the original termination date, contact your Scientific Director and submit the Request for Cancellation form found in the "Deliverables" section at https://proposalcentral.com.

In the event a grant is canceled, the institution is only entitled to the prorated amount of the award accumulated between the start and termination dates. The Society assumes no responsibility for expenditures in excess of the prorated amount. If an award is canceled after the initiation of the grant period, a final report will be due within 60 days of the termination date describing the work completed up to that point.

The ACS may cancel a grant at its sole discretion if the institution fails to comply with the terms and obligations related to the grant.

16. ADDITIONAL ACS GRANT POLICIES
See the standard ACS Grant Policies document for the following information:
- Tobacco-Industry Funding Policy
- Collaborations with ACS Intramural Scientists
APPENDIX A: GUIDELINES FOR MAINTAINING RESEARCH AND PEER REVIEW INTEGRITY

The American Cancer Society seeks excellence in the discovery and dissemination of knowledge regarding the cause, prevention, detection, diagnosis, treatment, survivorship, and health policy of cancer. This requires that all individuals affiliated with, or funded by, the American Cancer Society adhere to the highest standards of professional integrity. Grant reviewers for the American Cancer Society will also be held to the highest codes of conduct and integrity in performing their essential function of peer review.

The American Cancer Society provides grant funds for individuals at academic and other not-for-profit institutions to promote cancer-related training, research, and treatment. This represents a contractual relationship with such institutions, and it is an accepted responsibility and obligation of those institutions to provide policies and procedures for their faculty, staff, and students that address possible misconduct in training, research, and treatment of patients. Moreover, it is the responsibility and obligation of faculty, students, and staff engaged in scientific research and training to be aware of policies and procedures for addressing possible misconduct at their institutions, and to follow those procedures in reporting possible misconduct.

While questions of the integrity of applicants, grantees, and reviewers are very infrequent, they do occur. Ensuring that all questions regarding research integrity are handled in a discrete, but thorough, manner is the responsibility of the Scientific Program Directors managing the review process and portfolios of funded grants, and of the Senior Vice President for Extramural Discovery Science.

The actions of the Scientific Directors and the Senior Vice President for Extramural Discovery Science must ensure:

- the confidentiality and anonymity of the individual raising the question of misconduct,
- the integrity of the American Cancer Society and its review processes,
- the rights of the individual accused of misconduct, and
- their own credibility and integrity.

Article 1

Standards and Definitions:

1.1 Research Misconduct by Applicants or Grantees

The American Cancer Society uses the following definitions related to scientific misconduct outlined in the Federal Guidelines [Federal Register, Vol. 65, No. 235, pg. 76260-76264].

- Research misconduct is defined as fabrication, falsification, or plagiarism in proposing, performing, or reviewing research, or in reporting research results.¹
- Research, as used herein, includes all basic, applied, and demonstration research in all fields of science, engineering, and mathematics. This includes, but is not limited to, research in economics, education, linguistics, medicine, biology, chemistry, psychology, natural sciences, social sciences, and statistics, and all research involving human subjects or animals.¹
• Fabrication is defined as making up data or results and recording or reporting them.\(^1\)

• Falsification is defined as manipulating research materials, equipment, or processes, or changing or omitting data or results such that the research is not accurately represented in the research record.\(^1\)

• The research record is defined as the record of data or results that embody the facts resulting from scientific inquiry. It includes, but is not limited to, research proposals, laboratory records (both physical and electronic), progress reports, abstracts, theses, oral presentations, internal reports, and journal articles.\(^1\)

• Plagiarism is defined as the appropriation of another person’s ideas, processes, results, or words without giving appropriate credit.

• Research misconduct does not include honest error or differences of opinion.\(^1\)

• Reported Qualifications must be accurate (e.g., years since degree earned).

1.2 Research Misconduct by Peer Review Committee Members

The American Cancer Society has adopted the following definitions of misconduct by members of a Peer Review Committee. Misconduct in review is defined as:

• Review for an application for which there is a clear conflict of interest (COI) between the reviewer and applicant. Examples of a COI include joint work on a recent publication, collaboration on a grant, or having trained together.

• Failure to notify ACS personnel of actual, potential, perceived, or potentially perceived conflicts of interest.

• Any communication pertaining to review-related materials between a reviewer and an applicant or applicant’s mentor, when the application includes an element of training.

• Any communication of the unpublished content of a grant application by a reviewer with any individual who is not a permanent or ad hoc member of the peer review committee to which an application is assigned, or who has not been approved by the Scientific Director for such communication.

• Any use of the unpublished content or concepts of a grant application in pursuit of scientific or career goals by a reviewer.

• Any review or use of the contents of a grant application by a reviewer who might have, or might be perceived to have, a conflict of interest with the applicant or his/her mentor, when the application includes an element of training.

1.3 Confidentiality Standard for Reviewers

To preserve the integrity of the peer review process, all parties involved in the review process must adhere to the following practices regarding confidentiality and non-disclosure:

\(^1\) The above definitions are outlined in the Federal Guidelines [Federal Register, Vol.65, No.235, pg.: 76260-76264]
• Reviewers must not discuss applications reviewed with any individual not designated as a part of the review process, and especially not with applicants or their mentors in the case of training grants, either before or after the peer review meetings.

• Any inquiries to a peer review panel member regarding an application from an applicant, PI, Co-PI, consultant, or their mentor, to a member of a peer review committee or the Extramural Discovery Advisory Council must be reported immediately to the Scientific Director.

• All materials related to the review process must be destroyed or given to the Research Program Manager at the end of the review meeting.

• For purposes of this standard, materials related to the review process include, but are not limited to paper, bound volumes, flash drives, electronic files accessed via the internet, and oral presentations or discussions.

1.4 Conflict of Interest Standard for Reviewers

To preserve the integrity of the peer review process, all participants in the process must adhere to these principles and practices:

• Reviewers must not be an employer or employee of an applicant and may not be employed by the same institution as an applicant within three years of the date of submission of an application.

• Reviewers must not be a party to any agreement for future employment or other agreement or arrangement with an applicant or any person listed as key personnel on an application.

• Reviewers must not have served as mentors or collaborators of an applicant within three years of the date of an application.

• Reviewers must not participate in the review of an application submitted by a standing member of a peer review committee serving on the same review committee, with the exception of Institutional Research Grants.

• Reviewers must not be under the health care of, or providing health care to, an applicant or any person listed as key personnel on an application.

• Reviewers must not have received, or have the potential to receive, direct financial benefit from the application.

• Reviewers must not be pursuing research projects which might be viewed as being in direct competition with applicants or their collaborators and colleagues. Nor should a reviewer have potential to receive direct benefit from an application’s rejection for funding.

• Reviewers must not have any cause of action, dispute, or claim against, or any long-standing scientific or personal differences with, the applicant or any person listed as key personnel on an application.

Articles II
Policies:

2.1 Policy Governing Misconduct by Applicants and Grantees
2.1.1 Scientific Misconduct by Applicants:
Any allegations of scientific misconduct must be brought to the immediate attention of the Scientific Director in charge of the Peer Review Committee that is responsible for reviewing the work in question. If possible, allegations of scientific misconduct on the part of an applicant in the submission of a grant proposal should be raised in advance of the review meeting. The Scientific Director will then bring the allegation to the attention of the Senior Vice President for Extramural Discovery Science at ACS. The Senior Vice President for Extramural Discovery Science will evaluate the allegation and make a determination on the misconduct issue and the appropriate next steps to be taken to engage in further investigation or action in accordance with Article III, section 3.1.1, “Procedure for Handling Allegations of Scientific Misconduct by Applicants.”

2.1.2 Scientific Misconduct by Grantees:
In instances where alleged scientific misconduct occurs after the awarding of a grant, such as in the publication of falsified data, the Scientific Director will bring the allegation to the attention of the Senior Vice President for Extramural Discovery Science at ACS. The Senior Vice President for Extramural Discovery Science will evaluate the allegation and make a determination of the appropriate steps to be taken to engage in further investigation or action as defined in Article III, section 3.1.2, “Procedure for Handling Allegations of Scientific Misconduct by Grantees.”

2.1.3 Professional Misconduct by Grantees:
In instances where alleged professional misconduct occurs after the awarding of a grant, such as an allegation of sexual harassment by a principal investigator, the grantee should follow the reporting guidelines in Article III, section 3.1.3, “Procedure for Handling Allegations of Professional Misconduct by Grantees.”

2.2 Policy Governing Misconduct by Peer Review Committee Members

2.2.1 Confidentiality:
Confidentiality is at the heart of the peer review process and is imperative for objective evaluation and free expression in the review process. The applicant-reviewer relationship is a privileged alliance founded on the ethical rule of confidentiality. To maintain the essence and integrity of the peer review process, the Society and its appointed peer reviewers must ensure and be assured that the confidentiality of the applicant’s information, the contents of the grant application, and the proceedings of the review panel will be maintained. Such confidentiality adheres when a person discloses information to another with the understanding that the information will not be divulged to others without the consent of the party who disclosed the information, or as otherwise required by law. In the context of peer review, this rule upholds the applicants’ rights to have the information they submit, whether in proposal form or in communications, kept confidential. The rule also ensures that those involved in the review process maintain their obligation to keep confidential any information concerning an application. In fact, the very existence of a submission should not be revealed (or confirmed), to anyone other than those within the review process unless and until the application is funded. To this end, all contents, evaluation and discussion of applications shall be confined to Peer Review Committee (PRC) members and ACS staff personnel (Scientific Director, Senior Vice President for Extramural Discovery Science, Program staff), responsible for managing the review process of that PRC. For these purposes, reviewers include all standing, stakeholder and ad hoc reviewers of PRCs and members of the Extramural Discovery Science Advisory Board. In rare and specific instances, discussion of applications with, or in the presence of, non-committee members can occur after obtaining the written consent of the Scientific Director. Reviewers
must not discuss reviews with applicants or their mentors in the case of training grants, either before or after the review meetings. Reviewers also must not communicate the contents of any grant applications with individuals not associated with the review process. Any materials related to the review process must be disposed of at the meeting, and all final critiques given to the Scientific Director.

If an allegation of a breach of reviewer confidentiality is brought forward, that allegation will be communicated to the Senior Vice President for Extramural Discovery Science who will determine if an investigation of that allegation is warranted. The Senior Vice President for Extramural Discovery Science will then follow the appropriate steps as defined in Article III, section 3.2 “Procedure for Handling Reviewer Misconduct and Conflicts of Interest.”

2.2.2 Conflict of Interest:

An objective evaluation of grant proposals is essential to the peer review process. In achieving this goal, there must be no conflict of interest, apparent conflict of interest or pending future conflict of interest between any participant in the review process and the applicants or their collaborators and colleagues. In this setting, reviewers include standing, stakeholder and ad hoc Peer Review Committee (PRC) members and members of the ACS Extramural Discovery Advisory Council responsible for, and participating in, the review process. There are numerous bases for conflicts of interest, and these can include: employment, professional relationships, personal relationships, financial benefit, industry affiliation or other interests. The conflicts can be real or perceived. For Definitions of Conflict of Interest, refer to Section 1.5.

Reviewers may not make use of any of the contents of a grant for their own research purposes or those of their collaborators and colleagues. Reviewers must exercise proper due diligence in investigating and disclosing any potential conflict of interest that might exist between themselves and an applicant or the applicant’s collaborators or mentors. The Conflict of Interest Statement attached as EXHIBIT A shall be submitted to the Society prior to the beginning of Peer Review.

If an allegation of a reviewer conflict of interest is brought forward, that allegation will be communicated to the Senior Vice President for Extramural Discovery Science who will determine if an investigation of that allegation is warranted. The Senior Vice President for Extramural Discovery Science will then follow the appropriate steps as defined in Article III, section 3.2, “Procedure for Handling Reviewer Misconduct and Conflicts of Interest”.

Reviewers and stakeholders must submit electronically signed forms confirming compliance with required terms for confidentiality, conflict of interest, and relationship disclosure.

Article III

Procedures for Handling Conflicts of Interest and Allegations or Findings of Misconduct:

To ensure the integrity of the peer review process and the integrity of ACS-sponsored research, it is necessary that the procedures for dealing with allegations of misconduct be clearly understood by all reviewers and ACS personnel. Procedures for handling allegations of misconduct by applicants, grantees and reviewers are detailed in the following sections.

3.1 Procedures for Handling an Allegation of Scientific Misconduct by Applicants or Grantees

1.1.1 Procedure for Handling Allegations of Scientific Misconduct by Applicants:

In the event that an allegation of scientific misconduct by an applicant is brought forward to a Scientific Director or other ACS staff, all effort must be made to investigate the validity of the
allegation while maintaining the confidentiality of the individual making the allegation, the anonymity of the person against whom the allegation is made, and the integrity of the review process. The Scientific Director must immediately inform the Senior Vice President for Extramural Discovery Science of the allegation and provide all relevant information regarding the allegation. It is the Senior Vice President’s responsibility to evaluate the likelihood of scientific misconduct; and, if warranted, it is the Senior Vice President’s responsibility to contact the appropriate institutional office at the applicant’s institution regarding the allegation. The Senior Vice President for Extramural Discovery Science will then serve as the point of contact between the ACS and the institutional official[s] handling issues of scientific misconduct.

If determined to be appropriate, the Senior Vice President for Extramural Discovery Science will forward an allegation of scientific misconduct and all pertinent information to the Research Integrity Officer at the institution sponsoring the grant application in question or at which the alleged scientific misconduct was carried out. If there is not a Research Integrity Officer, the Dean of the School in question or its chief academic officer will be contacted. In the instance that the person[s] making the allegation does not contact the American Cancer Society but raises the allegation of scientific misconduct with the appropriate institutional official according to their established institutional procedures, it is the responsibility of the institution to contact the American Cancer Society regarding the allegation, any investigation of the allegation, and the outcome of that investigation. All such correspondence will be held in strict confidence and will not be made public by the American Cancer Society irrespective of the outcome of the investigation. The American Cancer Society assumes no responsibility in carrying out the investigation of scientific misconduct, or in determining an individual’s innocence or guilt of the allegation of scientific misconduct. However, acceptance or nonacceptance of the findings of the institutional investigation is at the discretion of the Society, and additional clarification may be requested.

Allegations of scientific misconduct in a grant application may be made by individuals who are colleagues, trainees, or reviewers. In the instance that an allegation of scientific misconduct is made in reference to a grant application, the Senior Vice President for Extramural Discovery Science will contact the institutional official at the sponsoring research institution and seek to follow their established protocol for investigating such allegations. If an investigation is deemed necessary, it will be the responsibility of the sponsoring institution to carry out the investigation, to keep the ACS aware of the progress, and to report the outcome of the investigation to the Senior Vice President for Extramural Discovery Science. The written report should include findings, actions taken, and any pending actions.

In fairness to the applicant, the review process must continue while the allegation of scientific misconduct undergoes assessment. Review may continue either in the standing review committee or under the By-pass to Council review mechanism. Under no circumstance should a reviewer, Scientific Director, or ACS staff raise the issue of the allegation in a peer review meeting or meeting of the ACS Extramural Discovery Advisory Council. If that were to occur, review of that application could not be completed without bias; and review of the application must therefore be discontinued immediately and deferred to ad hoc reviewers or the Extramural Discovery Advisory Council. If a reviewer suspects scientific misconduct, which is discovered at the time of the meeting, it is appropriate to request the Chair of the PRC or Council take a "break" and discuss the issue privately with the Scientific Director. The Scientific Director will then take the proscribed administrative steps following the adjournment of the review meeting.

The ACS will complete the process of peer review of the application but will suspend any administrative action which would result in funding of the award in question until the resolution of the investigation. At the conclusion of the investigation, the ACS will require the Office of Research Integrity or comparable entity at the applicant’s sponsoring institution to provide a
written statement detailing the results of the investigation including any actions taken, or actions pending. Failure of the institution to carry out such an investigation in a timely manner or to provide written results of the investigation will result in the administrative disapproval of the application. If the applicant is absolved of any scientific misconduct, the ACS will reinstitute administrative action that can result in funding for the award if it was approved and is within the fundable pay-line. In the instance that scientific misconduct has occurred, the ACS will administratively inactivate the application. Also, in the case of a finding of scientific misconduct, the investigator may no longer be eligible to participate in ACS funded awards, either as principal investigator, coinvestigator, collaborator, mentor, or consultant. The investigator also may not be eligible to serve in any capacity in reviewing ACS grant proposals.

3.1.2 Procedure for Handling Allegations of Scientific Misconduct by Grantees:

In the event that an allegation of scientific misconduct by a grantee is brought forward to a Scientific Director or other ACS staff, all effort must be made to investigate the validity of the allegation while maintaining the confidentiality of the individual making the allegation and the anonymity of the person against whom the allegation is made. The Scientific Director, or ACS staff contacted about the alleged scientific misconduct, must immediately inform the Senior Vice President for Extramural Discovery Science of the allegation and provide all relevant information regarding the allegation. It is the Senior Vice President’s responsibility to evaluate the likelihood of scientific misconduct; and, if warranted, it is the Senior Vice President for Extramural Discovery Science’s responsibility to contact the appropriate institutional office at the applicant’s institution regarding the allegation. The Senior Vice President for Extramural Discovery Science will then serve as the point of contact between the ACS and the institutional official[s] handling issues of scientific misconduct.

If determined to be appropriate, the Senior Vice President for Extramural Discovery Science will forward an allegation of scientific misconduct and all pertinent information to the Research Integrity Officer at the institution sponsoring the grant in question or at which the alleged scientific misconduct was carried out. If there is not a Research Integrity Officer, the Dean of the School in question or its chief academic officer will be contacted. In the instance that the person[s] making the allegation does not contact the American Cancer Society but raises the allegation of scientific misconduct with the appropriate institutional officer according to their established institutional procedures, it is the responsibility of the institution to contact the American Cancer Society regarding the allegation, any investigation of the allegation, and the outcome of that investigation. All such correspondence will be held in strict confidence and will not be made public by the American Cancer Society irrespective of the outcome of the investigation. The American Cancer Society assumes no responsibility in carrying out the investigation of scientific misconduct, or in determining an individual’s innocence or guilt of the allegation of scientific misconduct. However, failure of the institution to immediately notify ACS of an allegation and/or investigation of scientific misconduct, or to carry out an investigation in a timely manner, or to provide written results to include findings, action taken, or any pending actions of the investigation, is in non-conformance with the terms and obligations of the grant and may result in the suspension of ACS funds for all grants awarded at the institution, to be decided by ACS in its sole discretion. Acceptance or non-acceptance of the findings of the institutional investigation is at the discretion of the American Cancer Society, and additional clarification may be requested.

If the investigator has an active ACS award, funding of that award will be suspended until the allegation has either been confirmed or be proven to be erroneous. If the allegation is proven not to have merit, the award may be reinstituted by ACS at the date of notification of those findings by the sponsoring institution. If the allegation of scientific misconduct is confirmed, the award will be terminated and any residual funds, as of the date of notification of the sponsoring
institution of the allegation, must be returned to the ACS. In the case of a finding of scientific misconduct, the investigator may no longer be eligible to participate in ACS funded awards, either as principal investigator, co-investigator, collaborator, mentor, or consultant. The investigator may also not be eligible to serve in any capacity in reviewing ACS grant proposals.

The publication of data serves to further the interests of the scientific pursuit, and specifically in the case of the ACS, the pursuit of eliminating the burden of cancer. Therefore, it is incumbent on both the ACS and the scientific community to ensure that any instances of misrepresentation of findings in a scientific study are apparent to the scientific community. To that end, a finding of falsification or misrepresentation of data in a published forum must be reported to the editor-in-chief of the journal in which such data is reported. It is the responsibility of the Senior Vice President for Extramural Discovery Science to coordinate such notification with the appropriate sponsoring institutional official according to their established policies and in conjunction with the policies of the journal. If the sponsoring institution does not have a policy regarding notification of the journal, then the Senior Vice President for Extramural Discovery Science will notify the editor-in-chief of the journal according to the journal's established policies. In the case of findings of falsification or misrepresentation of published data supported by ACS funds, any active grant[s] held by the responsible individual will be terminated and that individual may no longer be eligible for ACS funding via any mechanism as a principal investigator, co-investigator, collaborator, mentor, or consultant. That individual may also not be eligible to participate in ACS review in any capacity.

3.1.3 Procedure for Handling Professional Misconduct by Grantees:

For purposes of this subsection, the following definitions apply:

- **Finding/Determination:** (1) the final disposition of a matter under organizational policies and processes, to include the exhaustion of permissible appeals; or (2) a conviction of a sexual offense in a criminal court of law.

- **Administrative leave/Administrative action:** any temporary/interim suspension or permanent removal of an individual, or any administrative action imposed on an individual by the grantee under organizational policies or codes of conduct, statutes, regulations, or executive orders, relating to activities, including but not limited to, teaching, advising, mentoring, research, management/administrative duties, or presence on campus.

The grantee’s institution is required to notify ACS (1) of any finding/determination regarding the principal investigator (PI) or co-PI that demonstrates a violation of grantee policies or codes of conduct, statutes, regulations, or executive orders relating to sexual harassment, other forms of harassment, sexual assault, or other professional misconduct; and/or (2) if the PI or co-PI is placed on administrative leave or if any administrative action has been imposed on the PI or any co-PI by the awardee relating to any finding/determination or an investigation of an alleged violation of grantee policies or codes of conduct, statutes, regulations, or executive orders relating to sexual harassment, other forms of harassment, sexual assault, or other professional misconduct. Such notification must be submitted to the Senior Vice President for Extramural Discovery Science within ten days of (1) the finding/determination, (2) the date of the placement of the PI or co-PI on administrative leave, or (3) the date of the imposition of an administrative action, whichever is sooner. Each notification must include the following information:

- ACS grant number;
- Name of individual being reported;
- Type of notification (choose one):
3.2 Procedure for Handling Reviewer Misconduct and Conflicts of Interest

In the event that an allegation of reviewer misconduct, such as failure to acknowledge a conflict of interest, is brought forward to a Scientific Director or other ACS staff, all effort must be made to investigate the validity of the allegation while maintaining the confidentiality of the individual making the allegation, the anonymity of the person against whom the allegation is made, and the integrity of the review process. The Scientific Director or other ACS staff contacted regarding the alleged misconduct must immediately inform the Senior Vice President for
Extramural Discovery Science of the allegation and provide all relevant information regarding the allegation. It is the Senior Vice President for Extramural Discovery Science's responsibility to evaluate the likelihood of reviewer conflict of interest or misconduct; and, if warranted, it is the Senior Vice President for Extramural Discovery Science's responsibility to handle the investigation internally or to inform the appropriate institutional office at the reviewer's institution about the allegation if aspects of the reviewer misconduct violate any of the tenets of professional behavior established by that institution. The Senior Vice President for Extramural Discovery Science will then serve as the point of contact between the ACS and the institutional official handling issues of reviewer misconduct.

Some elements of reviewer misconduct represent conduct that will only have relevance for the appropriateness of the reviewer's role as a member of a peer review committee. For instance, if there is inappropriate communication between reviewer and applicant or an applicant's mentor or colleagues. In a case of this type, all elements of the investigation of the reviewer misconduct will be handled by ACS personnel at the discretion of the Senior Vice President for Extramural Discovery Science. In cases where a reviewer does not retain the confidentiality of the applicant's information or the content of his or her application, and makes that information available to a third party, it will be at the discretion of the Senior Vice President for Extramural Discovery Science to handle the issue internally at ACS or contact the Office of Research Integrity at the reviewer's institution, based upon an initial assessment of whether such conduct violates the rules of conduct established by that institution. For instance, if there is communication of the contents of a grant proposal by a reviewer to a competitor in the same field as the applicant, or if the reviewer makes use of findings or ideas in an application to further his or her own research interests. In the instance of such an allegation, the American Cancer Society assumes no responsibility for carrying out the investigation of scientific misconduct, or in determining an individual’s innocence or guilt of the allegation of misconduct. It is the institution’s responsibility to handle the misconduct according to their established procedures, and to submit to the Society a written report that includes findings, actions taken, and any pending actions. However, acceptance or non-acceptance of the findings of the institutional investigation is at the discretion of the Society, and additional clarification may be requested. In any instance of a finding of reviewer misconduct, that individual may no longer be eligible to serve in any capacity in reviewing ACS grant proposals and may be barred from receiving any ACS grant funds.

References:
